Compensation for cures: Why we should pay a premium for participation in ‘challenge studies’
Open Access
- 28 May 2019
- Vol. 33 (7), 792-797
- https://doi.org/10.1111/bioe.12596
Abstract
Antibiotic resistance is one of the most pressing public health problems humanity faces. Research into new classes of antibiotics and new kinds of treatments – including risky experimental treatments such as phage therapy and vaccines – is an important part of improving our ability to treat infectious diseases. In order to aid this research, we will argue that we should permit researchers to pay people any amount of money to compensate for the risks of participating in clinical trials, including ‘challenge studies’ that involve deliberately infecting patients. We think that standard worries about paying for participation in risky research are reducible to concerns that can be addressed with the right screening mechanisms.Keywords
This publication has 6 references indexed in Scilit:
- Ethical Criteria for Human Challenge Studies in Infectious Diseases: Table 1.Public Health Ethics, 2015
- Platforms for antibiotic discoveryNature Reviews Drug Discovery, 2013
- Informative inducement: Study payment as a signal of riskSocial Science & Medicine, 2010
- The expanding vaccine development pipeline, 1995–2008Vaccine, 2010
- Do Incentives Exert Undue Influence on Survey Participation? Experimental EvidenceJournal of Empirical Research on Human Research Ethics, 2008
- Challenge studies of human volunteers: ethical issuesJournal of Medical Ethics, 2004